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Background
By the end of 2009, the number of HIV-1 infected
patients on RTI-based 1
st line and PI-based 2
nd line
ARV regimen in Cambodia reached 34,000 and 1,500,
respectively. We already reported good virological and
immunological responses after 1 to 4 years in cohorts of
patients on 1
st line and more recently, among an Esther
cohort of 70 patients after 2 years on LPVr-based 2
nd
line regimen. However, emergence of LPV resistant
associated mutations is becoming a major concern in
low and middle income countries.
Objective
This study aimed to describe the resistance pattern of
both the protease (PR) and integrase (IN) coding regions
in HIV-1 CRF01-AE infected patients failing LPV-based
2
nd line regimen in Cambodia.
Methods
Analysis of the Protease and Integrase drug resistance
genotyping of 95 HIV-1 strains infected patients pre-
senting detectable viral load on LPV/r-based 2
nd line
regimen in Cambodia.
Results
Lack of amplification in PR gene was observed for 18/95
presenting low viral load (median VL: 2.9Log10 copies/
ml [IQR: 2.8-3.4]). The 77 other CRF01_AE strains,
harbored polymorphism mutation in position M36, H69
and L89 conferring possibly resistance to TPV/r. Forty-
nine (median VL: 5Log10 copies/ml [IQR: 4 - 5.5]) did
not present any other PI associated resistance mutation.
In contrast, 28 patients showed multiple resistances to
PI. The median duration on LPV/r regimen was 34.5
months [IQR: 23.5 – 53.3] and the median VL was
5Log10 copies/ml [IQR: 4.3-5.6]. Twenty-five patients
were resistant to LPV/r (7 possibly resistant). Twenty-
seven were resistant to IDV, 21 and 19 to ATV/r and
FPV/r, respectively. Twenty-five were resistant to NFV
(10 possibly), 22 resistant to SQV/r (9 possibly). Seven
showed resistance to DRV/r (5 possibly). Finally, exclud-
ing possible resistance, 21/28 (75%) was resistant for at
least 3 PIs. Clinical investigation revealed that most of
these 28 patients starting several RTIs and PIs early
around 2000. All of them were sensitive to raltegravir,
elvitegravir (integrase inhibitors), and etravirine (Non-
Nucleoside reverse transcriptase inhibitorse).
Conclusion
This study indicates that 28/95 (29.5%) of Cambodian
patients presenting detectable viral load on LPV/r–based
2
nd line regimen developed resistance mutation for a
large number of PIs. Most of them were not naïve for
PI before LPV/r initiation. These results highlight an
urgent need to evaluate the efficacy of LPV/r-based 2
nd
line regimen at the national levels, allowing to design of
a next 3
rd line ARV regiment in low and middle income
countries. * Correspondence: njanin@pasteur-kh.org
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